D.A. Davidson & Co’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

D.A. Davidson & Co’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-4,070	Closed	-$342K	–	1159
2017 Q4	$342K	Sell	4,070 -695	-15%	-$68.2K	0.01%	796
2017 Q3	$550K	Buy	4,765 +705	+17%	+$74.2K	0.01%	651
2017 Q2	$474K	Buy	4,060 +475	+13%	+$59K	0.01%	644
2017 Q1	$442K	Sell	3,585 -20	-0.6%	-$2.62K	0.01%	645
2016 Q4	$491K	Buy	+3,605	New	+$640K	0.01%	654
2015 Q4	–	Sell	-22	Closed	-$3K	–	2307
2015 Q3	$3K	Hold	22	–	–	﹤0.01%	2080
2015 Q2	$4K	Buy	+22	New	+$5.39K	﹤0.01%	2044

Other funds holding BLCM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ascend Capital Orinda, California $1.99B AUM 10.36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

D.A. Davidson & Co's BLCM Position: Q1 2018 in Review

D.A. Davidson & Co sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q1 2018, closing a stake of 4,070 shares — an estimated $342K sold.

D.A. Davidson & Co first reported a position in BLCM in Q2 2015 and held it in 7 quarters. The position peaked at $550K in Q3 2017. 90 funds tracked by Wall St. Rank hold BLCM as of Q1 2018.

D.A. Davidson & Co reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
D.A. Davidson & Co sold 4,070 Bellicum Pharmaceuticals, Inc. shares in Q1 2018, an estimated $342K.
D.A. Davidson & Co first reported a position in Bellicum Pharmaceuticals, Inc. in Q2 2015 and held it in 7 quarters.
D.A. Davidson & Co's Bellicum Pharmaceuticals, Inc. position peaked at $550K in Q3 2017.
90 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q1 2018.

Based on D.A. Davidson & Co's 13F filing for Q1 2018, filed 4 May 2018.